Evidence map›Paper›PMID 40889412›Full record

ReviewEnvironment international2025

Metabolome informs about the chemical exposome and links to brain health.

Matej Orešič, Naama Karu, Haoqi Nina Zhao, Arthur Moseley, Thomas Hankemeier, David S Wishart, Pieter C Dorrestein, Oliver Fiehn, Tuulia Hyötyläinen, Rima Kaddurah Daouk and 1 more

Abstract readReview
In one paragraph

Review in Environment international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matej OrešičSchool of Medical Sciences, Faculty of Medicine and Health, Örebro University, SE-702 81 Örebro, Sweden; Turku Bioscience Centre, University of Turku and Åbo Akademi University, FI-b0eb0 Turku, Finland; Department of Life Technologies, University of Turku FI-b00n Turku, Finland. Electronic address: matej.oresic@oru.se.
Naama KaruTasmanian Independent Metabolomics and Analytical Chemistry Solutions (TIMACS), Hobart, Tasmania, Australia.
Haoqi Nina ZhaoCollaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
Arthur MoseleyDuke Center for Genomic and Computational Biology, Duke University, Durham, NC, USA.
Thomas HankemeierMetabolomics & Analytics Centre, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, the Netherlands.
David S WishartDepartment of Biological Sciences, University of Alberta, Edmonton, AB, Canada.
Pieter C DorresteinCollaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
Oliver FiehnWest Coast Metabolomics Center, University of California Davis, Davis, CA, USA.
Tuulia HyötyläinenSchool of Science and Technology, Örebro University, SE-702 81 Örebro, Sweden.
Rima Kaddurah DaoukDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA; Department of Medicine, Duke University, Durham, NC, USA; Duke Institute of Brain Sciences, Duke University, Durham, NC, USA. Electronic address: rima.kaddurahdaouk@duke.edu.
Alzheimer Gut Microbiome Project

Funding

Project 4 - Mechanistic studies on the role of the gut microbiome in models for Alzheimer's diseaseU19AG063744 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Rima F Kaddurah-Daouk · 2019 to 2026
$54.1M
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-ADU01AG061359 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2018 to 2022
$10.0M
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its TrajectoryU01AG088562 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Oliver Fiehn, LEE E. GOLDSTEIN · 2024 to 2026
$7.2M
NIA NIH HHS U01 AG061359NIA NIH HHS U01 AG088562NIA NIH HHS U19 AG063744
6 · The paper itself

Abstract

The metabolome is an intermediate phenotype, summarizing the profile of all small molecules (<1.5 kDa) in biospecimens. The metabolome provides a readout for the net influence of the chemical exposome, diet, gut microbiome, and genome on human health. Metabolic changes observed in exposome studies may thus provide clues about adverse outcome pathways related to cancer, diabetes, heart disease, cognitive impairment and other neurological conditions such as Alzheimer's disease (AD). Whilst the number of human cohort studies including both metabolomic and exposomic profiles is increasing, they are particularly limited in the domain of neurological conditions. Environmental exposures and chemical toxicants are known to have significant effects on the brain, gut microbiome, and gut-brain axis. Environmental chemicals of greatest interest include bisphenols, phthalates, persistent organic pollutants such as polychlorinated biphenyls (PCBs) and per- and poly-fluoroalkyl substances (PFAS), heavy metals, chemicals from household products and pesticides/herbicides; all of which may increase the risk of AD as they impact relevant biochemical mechanisms, especially with chronic exposure. In this review we describe how the chemical exposome can be assessed, including the approach our consortium is taking in the context of AD. Further, we review the current evidence about the impact of the chemical exposome on cognition as well as its influence on the risk and pathogenesis of AD. Finally, we highlight our approach to study the exposome in AD as part of large national and international collaborative efforts on the topic.

Indexed as

ExposomeMetabolomeAlzheimer DiseaseBrainEnvironmental PollutantsHumansEnvironmental PollutantsAlzheimer’s diseaseBrain healthChemical exposureEnvironmental exposureExposomeMetabolomics

Identifiers

PMID40889412
PMCPMC12633721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.